



ANTIMICROBIAL SUSCEPTIBILITY PROFILE (01/01/2023 to 12/31/2023)
MedStar St. Mary's Hospital

|  Gram Negative Organisms | Percent Susceptible | | | | | | | | | | | | | | | | | | | |
|---|---------------------|-------------|------------|----------------------|-----------|------------------------------------|---------------------------------|----------|-------------|-------------|---------------|-----------------|---------------|--------------|-----------|-----------------|-------------------------|--------------|---------------|--------------------|
| | Number of Isolates | Amikacin*** | Ampicillin | Ampicillin/sulbactam | Aztreonam | Cefazolin (Systemic ^a) | Cefazolin (Urine ^b) | Cefepime | Ceftazidime | Ceftriaxone | Ciprofloxacin | ESBL (Negative) | Gentamicin*** | Levofloxacin | Meropenem | Nitrofurantoin* | Piperacillin/tazobactam | Tetracycline | Tobramycin*** | Trimethoprim/Sulfa |
| <i>Acinetobacter baumannii</i> ** | 13 | 90 | - | 90 | - | - | 84 | 90 | 55 | 90 | - | 83 | - | 98 | 71 | - | - | - | 90 | - |
| <i>Enterobacter cloacae</i> | 110 | 100 | 1 | 0 | 83 | - | 89 | 82 | 82 | 87 | 100 | 96 | - | 98 | 71 | 88 | 86 | 92 | 93 | - |
| <i>Escherichia coli</i> | 911 | 100 | 54 | 59 | 90 | 52 | 83 | 92 | 89 | 90 | 66 | 91 | 91 | 100 | 98 | 97 | 75 | 90 | 78 | - |
| <i>Klebsiella pneumoniae ssp pneumoniae</i> | 231 | 100 | 0 | 79 | 90 | 61 | 88 | 91 | 89 | 90 | 86 | 90 | 96 | - | 98 | 55 | 90 | 86 | 93 | 87 |
| <i>Morganella morganii</i> | 40 | 100 | 0 | 8 | 100 | - | - | 100 | 85 | 90 | 60 | 100 | 90 | - | 100 | 0 | 98 | 44 | 93 | 78 |
| <i>Proteus mirabilis</i> | 128 | 91 | 79 | 87 | 95 | 0 | 83 | 93 | 93 | 66 | 100 | 87 | - | 0 | 98 | 0 | 86 | 83 | - | - |
| <i>Pseudomonas aeruginosa</i> | 148 | 98 | - | - | 79 | - | - | 95 | 91 | - | 80 | - | - | 90 | - | 89 | - | 98 | - | - |
| <i>Serratia marcescens</i> | 31 | 100 | 0 | 0 | 88 | - | - | 88 | 88 | 78 | 94 | 100 | 100 | - | 90 | 0 | 84 | - | 84 | - |
| <i>Stenotrophomonas maltophilia</i> ** | 19 | - | - | - | - | - | - | - | 53 | - | - | - | - | 84 | - | - | - | - | - | 95 |

|  Gram Positive Organisms | Percent Susceptible | | | | | | | | | | | | | | | |
|---|---------------------|------------|--------------------------|------------------------------|-------------|------------|-------------|--------------|-----------|-----------------|-----------|-------------------------|-----------------------------|--------------|--------------------|------------|
| | Number of Isolates | Ampicillin | Ceftriaxone (meningitis) | Ceftriaxone (non-meningitis) | Clindamycin | Daptomycin | Doxycycline | Erythromycin | Linezolid | Nitrofurantoin* | Oxacillin | Penicillin (meningitis) | Penicillin (non-meningitis) | Tetracycline | Trimethoprim/Sulfa | Vancomycin |
| <i>Enterococcus faecalis</i> | 214 | 100 | - | - | - | 100 | - | - | 100 | 100 | - | - | - | 32 | - | 93 |
| <i>Enterococcus faecium</i> | 35 | 25 | - | - | - | 97 | - | - | 89 | - | - | - | - | 27 | - | 77 |
| Methicillin resistant <i>Staphylococcus aureus</i> (MRSA)*** | 149 | - | - | - | 66 | 100 | 97 | 16 | 100 | - | 0 | - | - | 89 | 81 | 100 |
| Methicillin sensitive <i>Staphylococcus aureus</i> (MSSA) | 170 | - | - | - | 73 | 100 | 96 | 65 | 100 | - | 100 | - | - | 86 | 98 | 100 |
| <i>Staphylococcus coagulase-negative</i> | 305 | - | - | - | 80 | 100 | 98 | - | 100 | - | 57 | - | - | - | - | 100 |
| <i>Streptococcus pneumoniae</i> ** | 19 | - | 90 | 100 | 88 | - | - | 53 | 100 | - | - | 84 | 90 | 88 | 65 | 100 |

Percent Susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient

(-) Drug not tested or drug not indicated

(*) Tested on urine isolate only

(**) Data on the number of isolates less than 30 may not be statistically significant

(***) MRSA rate of the institution was 47% (****) Based on CLSI M100-32nd Ed breakpoints

^a Cefazolin (systemic), MIC ≤ 2 µg/mL, susceptible for infections other than uncomplicated UTIs

^b Cefazolin (urine), MIC ≤ 16 µg/mL, susceptible